We gebruiken cookies om ervoor te zorgen dat onze site zo soepel mogelijk draait. Als je doorgaat met het gebruiken van deze site, gaan we er vanuit dat je ermee instemt.
Selvita S.A, one of the largest preclinical contract research organizations in Europe, announced a strategic initiative to significantly expand its services portfolio and enter the field of biologic drug discovery and
Psoriasis vulgaris is a refractory skin inflammatory disorder with 80% of the cases belonging to the mild-to-moderate type, which can be controlled by topical treatment. Nevertheless, the drugs for ex...
Adipocyte fatty acid-binding protein (A-FABP) exacerbates cerebral ischaemia injury by disrupting the blood–brain barrier (BBB) through inducing expression of MMP-9. Circulating A-FABP levels positi...
The P2X3 receptor, a trimeric ionotropic purinergic receptor, has emerged as a potential therapeutic target for refractory chronic cough (RCC). Nevertheless, gefapixant/AF-219, the only marketed P2X3 ...